Cargando…

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if so...

Descripción completa

Detalles Bibliográficos
Autores principales:	Incorvaia, Lorena, Fanale, Daniele, Badalamenti, Giuseppe, Porta, Camillo, Olive, Daniel, De Luca, Ida, Brando, Chiara, Rizzo, Mimma, Messina, Carlo, Rediti, Mattia, Russo, Antonio, Bazan, Viviana, Iovanna, Juan Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595592/ https://www.ncbi.nlm.nih.gov/pubmed/33178494 http://dx.doi.org/10.1080/2162402X.2020.1832348

Ejemplares similares

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
por: Fanale, Daniele, et al.
Publicado: (2021)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
por: Fanale, Daniele, et al.
Publicado: (2022)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020)

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
por: Fanale, Daniele, et al.
Publicado: (2023)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
por: Shin, Jong, et al.
Publicado: (2021)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity
por: Blazquez, Juan-Luis, et al.
Publicado: (2018)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation
por: Liu, Wenping, et al.
Publicado: (2020)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

PD-1抑制剂Nivolumab治疗相关的皮肤毒性1例
Publicado: (2019)

IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
por: Ding, Guoping, et al.
Publicado: (2019)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
por: Rizzo, Mimma, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
por: Liu, Wai Nam, et al.
Publicado: (2022)

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma
por: Griffin, Liezel L., et al.
Publicado: (2018)

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
por: Nakahara, Yoshiro, et al.
Publicado: (2018)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b7u9ahjtvi96k2vamag6uc6el2